Medtronic Achieves 6% Organic Revenue Growth in Q3 FY26

Medtronic plc, a prominent player in healthcare technology, reported robust financial results for the third quarter of fiscal year 2026, which concluded on January 23, 2026. The company achieved a worldwide revenue of $9.017 billion, marking an increase of 8.7% compared to the previous year and an organic growth of 6%, surpassing the company’s guidance.

Geoff Martha, Medtronic’s chairman and chief executive officer, emphasized the significance of this quarter, stating, “Q3 marks another strong quarter, delivering 6% organic revenue growth, ahead of guidance, demonstrating the strength of our portfolio.” He attributed the company’s success to strategic investments in high-growth opportunities and expanding into new markets.

Financial Highlights and Yearly Guidance

In Q3, Medtronic’s operating profit reached $1.464 billion, resulting in an operating margin of 16.2%. When adjusted for non-GAAP measures, the operating profit surged to $2.177 billion, with a margin of 24.1%. The company’s net income for the quarter was reported at $1.143 billion, translating to a diluted earnings per share (EPS) of $0.89. Adjusted non-GAAP net income was higher at $1.750 billion, yielding a diluted EPS of $1.36.

Medtronic reiterated its guidance for fiscal year 2026, projecting an organic revenue growth of approximately 5.5% and a diluted non-GAAP EPS between $5.62 and $5.66. This guidance factors in potential tariff impacts estimated at around $185 million, consistent with previous forecasts.

Thierry Piéton, the company’s chief financial officer, noted the ongoing investments in research and development (R&D) to bolster Medtronic’s innovation pipeline. He remarked, “This quarter, we again delivered accelerated growth while investing decisively in our future.”

Segment Performance and Innovations

Medtronic’s cardiovascular portfolio experienced a notable year-over-year increase of 11%, driven significantly by the success of its Cardiac Ablation Solutions, which grew by 80% thanks to innovations in pulsed field ablation technology. Other segments also reported solid performance, with key areas such as Cardiac Rhythm & Heart Failure and Neuroscience contributing to the overall growth.

The company highlighted its commitment to improving healthcare outcomes through advanced technologies, which address over 70 health conditions worldwide. Medtronic’s diverse product offerings, including cardiac devices, surgical robotics, and patient monitoring systems, are central to its mission to alleviate pain and restore health.

Investors and analysts can access further details about Medtronic’s performance through a video webcast scheduled for today at 8:00 a.m. EST. The webcast will provide insights into the company’s business strategies and future outlook.

For more information, visit Medtronic’s official site or follow the company on LinkedIn.